Phenotypes associated with this allele
Allelic
Composition |
Ptpn11tm1Ckq/Ptpn11+
|
|
Genetic
Background |
involves: 129S6/SvEvTac * C57BL/6J |
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptpn11tm1Ckq mutation
(0 available);
any
Ptpn11 mutation
(43 available)
|
|
|
normal phenotype
|
|
• mice show no abnormalities
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation
(11 available);
any
Cd19 mutation
(56 available)
Ptpn11tm1Ckq mutation
(0 available);
any
Ptpn11 mutation
(43 available)
|
|
|
mortality/aging
neoplasm
|
|
• B cell lymphoblastic leukemia/lymphoma in 4 of 9 mice
|
|
|
• B cell lymphoblastic leukemia/lymphoma in 4 of 9 mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Lyz2tm1(cre)Ifo mutation
(14 available);
any
Lyz2 mutation
(41 available)
Ptpn11tm1Ckq mutation
(0 available);
any
Ptpn11 mutation
(43 available)
|
|
|
mortality/aging
neoplasm
|
|
• acute myeloid leukemia in 4 of 10 mice
|
immune system
|
|
• all mice develop myeloproliferative disease with enhanced myeloid cell proliferation and differentiation
• 2 of 10 mice develop accelerated myeloproliferative disease
|
hematopoietic system
|
|
• all mice develop myeloproliferative disease with enhanced myeloid cell proliferation and differentiation
• 2 of 10 mice develop accelerated myeloproliferative disease
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Hprt1tm1(CAG-cre)Mnn mutation
(1 available);
any
Hprt1 mutation
(1274 available)
Ptpn11tm1Ckq mutation
(0 available);
any
Ptpn11 mutation
(43 available)
|
|
|
Embryonic lethality in Ptpn11tm1Ckq/Ptpn11+ Hprt1tm1(CAG-cre)Mnn/Hprt1+ mice
mortality/aging
embryo
cardiovascular system
craniofacial
growth/size/body
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptpn11tm1Ckq mutation
(0 available);
any
Ptpn11 mutation
(43 available)
Tg(Mx1-cre)1Cgn mutation
(7 available)
|
|
|
Increased spleen weight in Ptpn11tm1Ckq/Ptpn11+ Tg(Mx1-cre)1Cgn/0 mice
mortality/aging
|
|
• by 56 weeks due to leukemia in pIpC-treated mice
|
hematopoietic system
|
|
• around the pro-B stage in pIpC-treated mice
|
|
|
• all pIpC-treated mice develop myeloproliferative disease (MPD)
• Mac-1+/Gr-1+ mature myeloid cells are increased
• 5 of 27 pIpC-treated mice exhibit accelerated MPD
|
|
|
• hyperproliferation in the liver and spleen in pIpC-treated mice
|
|
|
• progressive in pIpC-treated mice
|
|
|
• pIpC-treated mice exhibit decreased common myeloid progenitors, granulocyte macrophage progenitors, and megakaryocyte erythroid progenitors compared with wild-type mice
• however, common lymphoid progenitor numbers are normal
|
|
|
• extremely high after 32 weeks with leukemia infiltration in nonhematopoietic organs of pIpC-treated mice
|
|
|
• 3-fold in the bone marrow in pIpC-treated mice
|
|
|
• in the spleen of pIpC-treated mice
|
|
|
• hematopoietic stem cells are hyperactivated in pIpC-treated mice
• hematopoietic stem cell quiescent in pIpC-treated mice is decreased 2-fold while the S and G2/M phase were doubled compared to in wild-type mice
• apoptosis of hematopoietic stem cells in pIpC-treated mice is decreased compared to in wild-type mice
|
neoplasm
|
|
• T cell lymphoblastic leukemia/lymphoma in 9 of 27 pIpC-treated mice
|
|
|
• after 12 to 32 weeks of chronic myeloproliferative disease in pIpC-treated mice
|
|
|
• B and T cell lymphoblastic leukemia/lymphoma in pIpC-treated mice
|
|
|
• acute myeloid leukemia in 6 of 27 pIpC-treated mice
|
|
|
• B cell lymphoblastic leukemia/lymphoma in 2 of 27 pIpC-treated mice
|
cellular
|
|
• in bone marrow cells and splenocytes from pIpC-treated mice
|
|
|
• in pIpC-treated mice due to centrosome amplification
|
liver/biliary system
immune system
|
|
• around the pro-B stage in pIpC-treated mice
|
|
|
• all pIpC-treated mice develop myeloproliferative disease (MPD)
• Mac-1+/Gr-1+ mature myeloid cells are increased
• 5 of 27 pIpC-treated mice exhibit accelerated MPD
|
|
|
• extremely high after 32 weeks with leukemia infiltration in nonhematopoietic organs of pIpC-treated mice
|
endocrine/exocrine glands
|
|
• T cell lymphoblastic leukemia/lymphoma in 9 of 27 pIpC-treated mice
|
growth/size/body
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ptpn11tm1Ckq mutation
(0 available);
any
Ptpn11 mutation
(43 available)
Tg(Lck-cre)1Cwi mutation
(3 available)
|
|
|
endocrine/exocrine glands
|
|
• T cell lymphoblastic leukemia/lymphoma in 8 of 15 mice
|
mortality/aging
neoplasm
|
|
• T cell lymphoblastic leukemia/lymphoma in 8 of 15 mice
|
|
|
• T cell lymphoblastic leukemia/lymphoma in 8 of 15 mice
|
immune system
|
N |
• T and B cell development is normal
|
Analysis Tools